Search Results - "Baciuchka, M."

Exposure to genotoxic agents, host factors, and lifestyle influence the number of centromeric signals in micronuclei: a pooled re-analysis by Iarmarcovai, G, Bonassi, S, Sari-Minodier, I, Baciuchka-Palmaro, M, Botta, A, Orsière, T

“…We pooled data from three biomonitoring studies using the cytokinesis-block micronucleus assay in peripheral blood lymphocytes in combination with fluorescence…”
Get full text

Dose individualization of carboplatin after a 120-hour infusion schedule : Higher dose intensity but fewer toxicities by MERCIER, Cédric, CICCOLINI, Joseph, BACIUCHKA, Marjorie, BAGARRY-LIEGEY, Danielle, LACARELLE, Bruno, NOBLE, Alex, DURAND, Alain, FAVRE, Roger, POURROY, Bertrand, FANCIULLINO, Raphaelle, DUFFAUD, Florence, DIGUE, Laurence, TRANCHAND, Brigitte, MONJANEL-MOUTERDE, Suzanne, GUILLET, Pierre, NICOARA, Adriana

“…Carboplatin (CBDCA) is a widely used anticancer agent for which dose-effect and dose-toxicity relationships have been demonstrated, thus stressing the need for…”
Get full text

Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up by Fizazi, K., Carmel, A., Joly, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J.-M., Houede, N., Mourey, L., Theodore, C., Krakowski, I., Berdah, J.-F., Baciuchka Palmaro, M., Laguerre, B., Flechon, A., Ravaud, A., Brihoum, M., Culine, S., Le Teuff, G.

Get full text

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial by Lavaud, Pernelle, Gravis, Gwenaëlle, Foulon, Stéphanie, Joly, Florence, Oudard, Stéphane, Priou, Frank, Latorzeff, Igor, Mourey, Loïc, Soulié, Michel, Delva, Remy, Krakowski, Ivan, Laguerre, Brigitte, Théodore, Christine, Ferrero, Jean Marc, Beuzeboc, Philippe, Habibian, Muriel, Rolland, Frédéric, Deplanque, Gael, Pouessel, Damien, Zanetta, Sylvie, Berdah, Jean François, Dauba, Jerome, Baciuchka, Marjorie, Platini, Christian, Linassier, Claude, Tubiana-Mathieu, Nicole, Machiels, Jean Pascal, Kouri, Claude El, Ravaud, Alain, Suc, Etienne, Eymard, Jean Christophe, Hasbini, Ali, Bousquet, Guilhem, Culine, Stéphane, Boher, Jean-Marie, Tergemina-Clain, Gabrielle, Legoupil, Clémence, Fizazi, Karim

“…Androgen deprivation therapy (ADT) plus docetaxel is the standard of care in fit men with metastatic castration-naive prostate cancer (mCNPC) following results…”
Get full text

Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy by Duffaud, F., Digue, L., Mercier, C., Dales, J.P., Baciuchka-Palmaro, M., Volot, F., Thomas, P., Favre, R.

“…In this retrospective analysis, we report on the detailed management of 33 recurrent osteosarcoma patients from a population of 81 adolescents and adults…”
Get full text

Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients by Vicier, C., Faivre, L., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J.-M., Houede, N., Mourey, L., Theodore, C., Krakowski, I., Berdah, J.-F., Baciuchka, M., Laguerre, B., Flechon, A., Oudard, S., Habibian, M., Culine, S., Fizazi, K.

Get full text

Clinical Activity of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma (Mrcc) – Results of the Resume Study by Oudard, S., Goupil, M. Gross, Geoffrois, L., Guillot, A., Chevreau, C., Deville, J.L., Falkowski, S., Boyle, H., Palmaro, M. Baciuchka, Gimel, P., Laguerre, B., Laramas, M., Pfister, C., Topard, D., Rolland, F., Legouffe, E., Amela, E., Abadie-Lacourtoisie, S., Mahi, N.

Get full text

816PDCLINICAL ACTIVITY OF SUNITINIB RECHALLENGE IN METASTATIC RENAL CELL CARCINOMA (MRCC) – RESULTS OF THE RESUME STUDY by Oudard, S., Goupil, M. Gross, Geoffrois, L., Guillot, A., Chevreau, C., Deville, J.L., Falkowski, S., Boyle, H., Palmaro, M. Baciuchka, Gimel, P., Laguerre, B., Laramas, M., Pfister, C., Topard, D., Rolland, F., Legouffe, E., Amela, E., Abadie-Lacourtoisie, S., Mahi, N.

“…Abstract Aim: Sunitinib is a front-line standard of care in mRCC patients. Several studies have shown that a 2nd line with a TKI after sunitinib progression is…”
Get full text

Acentromeric micronuclei are increased in peripheral blood lymphocytes of untreated cancer patients by Baciuchka-Palmaro, M., Orsière, T., Duffaud, F., Sari-Minodier, I., Pompili, J., Bellon, L., De Méo, M., Digue, L., Favre, R., Botta, A.

“…Increased micronucleated cell rates, dicentric chromosomes, and other chromosomal damages have been reported in lymphocytes of cancer patients prior to the…”
Get full text

Safety results of a phase III trial evaluating ADT+ docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer patients (GETUG-AFU 15/0403) by Latorzeff, I., Esterni, B., Habibian, M., Delplanque, G., Theodore, C., Baciuchka, M., Dauba, J., Laguerre, B., Krakowski, I., Gravis, G.

“…Abstract only…”
Get full text

Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12) by Fizazi, K., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J., Houede, N., Mourey, L., Theodore, C., Krakowski, I., Berdah, J. F., Baciuchka, M., Kerbrat, P., Davin, J., Berille, J., Habibian, M., Ichante, J., Laplanche, A., Culine, S.

“…Abstract only…”
Get full text

Implication of clinical and paraclinical covariates in the pharmacokinetics of high dose MTX (HD-MTX) in patients with osteosarcoma by Dupuis, C., Mercier, C., Salas, S., Yang, C., Deville, J., Balti, M., Ciccolini, J., Iliadis, A., Baciuchka, M., Duffaud, F., Favre, R.

“…Abstract only 12022 Background: Methotrexate (MTX) is a mainstay in the treatment of ostosarcoma. MTX is characterized by a narrow therapeutic window, combined…”
Get full text

791OUpdated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up by Fizazi, K, Carmel, A, Joly, F, Delva, R, Gravis, G, Rolland, F, Priou, F, Ferrero, J-M, Houede, N, Mourey, L, Theodore, C, Krakowski, I, Berdah, J-F, Baciuchka Palmaro, M, Laguerre, B, Flechon, A, Ravaud, A, Brihoum, M, Culine, S, Le Teuff, G

Get full text

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial by Gravis, Gwenaelle, Dr, Fizazi, Karim, Prof, Joly, Florence, Prof, Oudard, Stéphane, Prof, Priou, Franck, MD, Esterni, Benjamin, MSc, Latorzeff, Igor, MD, Delva, Remy, MD, Krakowski, Ivan, Prof, Laguerre, Brigitte, MD, Rolland, Fréderic, MD, Théodore, Christine, MD, Deplanque, Gael, MD, Ferrero, Jean Marc, Prof, Pouessel, Damien, MD, Mourey, Loïc, MD, Beuzeboc, Philippe, MD, Zanetta, Sylvie, MD, Habibian, Muriel, Berdah, Jean François, MD, Dauba, Jerome, MD, Baciuchka, Marjorie, MD, Platini, Christian, MD, Linassier, Claude, Prof, Labourey, Jean Luc, MD, Machiels, Jean Pascal, Prof, El Kouri, Claude, MD, Ravaud, Alain, Prof, Suc, Etienne, MD, Eymard, Jean Christophe, MD, Hasbini, Ali, MD, Bousquet, Guilhem, MD, Soulie, Michel, Prof

“…Summary Background Early chemotherapy might improve the overall outcomes of patients with metastatic non-castrate (ie, hormone-sensitive) prostate cancer. We…”
Get full text

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial by Fizazi, Karim, Prof, Faivre, Laura, Lesaunier, François, MD, Delva, Remy, MD, Gravis, Gwenaëlle, MD, Rolland, Frédéric, MD, Priou, Frank, MD, Ferrero, Jean-Marc, Prof, Houede, Nadine, MD, Mourey, Loïc, MD, Theodore, Christine, MD, Krakowski, Ivan, MD, Berdah, Jean-François, MD, Baciuchka, Marjorie, MD, Laguerre, Brigitte, MD, Fléchon, Aude, MD, Ravaud, Alain, Prof, Cojean-Zelek, Isabelle, MD, Oudard, Stéphane, Prof, Labourey, Jean-Luc, MD, Chinet-Charrot, Paule, MD, Legouffe, Eric, MD, Lagrange, Jean-Léon, Prof, Linassier, Claude, Prof, Deplanque, Gaël, MD, Beuzeboc, Philippe, MD, Davin, Jean-Louis, MD, Martin, Anne-Laure, PharmD, Habibian, Muriel, Laplanche, Agnès, MD, Culine, Stéphane, Prof

“…Summary Background Early risk-stratified chemotherapy is a standard treatment for breast, colorectal, and lung cancers, but not for high-risk localised…”
Get full text

Insulin‐like growth factor (IGF)–binding protein‐3 (IGFBP‐3) proteolysis in patients with colorectal cancer: possible association with the metastatic potential of the tumor by Baciuchka, Marjorie, Remacle‐Bonnet, Maryse, Garrouste, Françoise, Favre, Roger, Sastre, Bernard, Pommier, Gilbert

“…The limited proteolysis of insulin‐like growth factor (IGF)–binding protein (IGFBP)‐3 is a key event in the regulation of endocrine bioavailability of IGFs…”
Get full text

Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial by Blanchard, Pierre, MD, PhD, Faivre, Laura, MSc, Lesaunier, François, MD, Salem, Naji, MD, Mesgouez-Nebout, Nathalie, MD, Deniau-Alexandre, Elisabeth, MD, Rolland, Frédéric, MD, Ferrero, Jean-Marc, MD, Houédé, Nadine, MD, Mourey, Loïc, MD, Théodore, Christine, MD, Krakowski, Ivan, MD, Berdah, Jean-François, MD, Baciuchka, Marjorie, MD, Laguerre, Brigitte, MD, Davin, Jean-Louis, MD, Habibian, Muriel, MD, Culine, Stéphane, MD, PhD, Laplanche, Agnès, MD, Fizazi, Karim, MD, PhD

“…Purpose The role of pelvic elective nodal irradiation (ENI) in the management of prostate cancer is controversial. This study analyzed the role of pelvic…”
Get full text

Therapeutic drug monitoring for dose individualization of cisplatin in testicular cancer patients based upon total platinum measurement in plasma by SALAS, Sébastien, MERCIER, Cédric, BALTI, Medhi, LACARELLE, Bruno, DUFFAUD, Florence, DURAND, Alain, FAVRE, Roger, CICCOLINI, Joseph, POURROY, Bertrand, FANCIULLINO, Raphaelle, TRANCHAND, Brigitte, MONJANEL-MOUTERDE, Suzanne, BACIUCHKA-PALMARO, Marjorie, DUPUIS, Charlotte, CHENGUANG YANG

“…Cisplatin (CDDP) is an anticancer agent widely used in testicular cancer, for which pharmacokinetic (PK)/pharmacodynamic relationships have usually been based…”
Get full text

Traitement anti-TNF et tumeur solide:À propos d'un cas by Salas, S., Mercier, C., Duffaud, F., Baciuchka, M., Jean, R., Durand, J.M., Favre, R.

Get full text

Population pharmacokinetic of total cisplatinum: Application to adaptative dosing with feed back in testicular cancer patient by Salas, S., Mercier, C., Ciccolini, J., Pourroy, B., Dupuis, C., Deville, J., Baciuchka-Palmaro, M., Durand, A., Duffaud, F., Tranchand, B., Favre, R.

“…Abstract only 2043 Background: Cisplatinum (CDDP) is major drug used in germ cell testicular cancer. Pharmacokinetics (PK)/pharmacodynamics relationships have…”
Get full text